LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
10. Dezember 2024 07:30 ET
|
LAVA Therapeutics N.V.
Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of...
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
03. September 2024 08:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LAVA Reports Second Quarter 2024 Financial Results and Business Update
20. August 2024 07:30 ET
|
LAVA Therapeutics N.V.
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for...
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
20. Juni 2024 07:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LAVA Announces Annual Meeting of Shareholders
10. Juni 2024 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
30. Mai 2024 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on...
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
21. Mai 2024 07:00 ET
|
LAVA Therapeutics N.V.
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from...
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
06. Mai 2024 16:05 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on...
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
20. März 2024 07:00 ET
|
LAVA Therapeutics N.V.
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for...
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
05. März 2024 07:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...